# Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

> **NCT04287686** · NA · WITHDRAWN · sponsor: **The First Affiliated Hospital of Guangzhou Medical University**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Recombinant human angiotensin-converting enzyme 2 (rhACE2)

## Key facts

- **NCT ID:** NCT04287686
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Without CDE Approval
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04287686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04287686, "Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04287686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*